CAS: 931399-19-8
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | GSK360A REF: TR-G797600CAS: 931399-19-8 | - - - | 326.00 €~1,383.00 € | Tue 17 Dec 24 |
 | GSK 360A REF: 3D-FG23706CAS: 931399-19-8 | Min. 95% | 206.00 €~1,047.00 € | Wed 18 Dec 24 |
 | GSK360A REF: TM-T27476CAS: 931399-19-8 | 98% | 907.00 €~2,337.00 € | Mon 27 Jan 25 |
GSK360A
Controlled ProductCAS:931399-19-8
Applications GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α …
Formula:
C17H17FN2O5
Color and Shape:
Neat
Molecular weight:
348.33
Ref: TR-G797600
| 5mg | 326.00 € | ||
| 10mg | 589.00 € | ||
| 25mg | 1,383.00 € |
Estimated delivery in United States, on Tuesday 17 Dec 2024
GSK 360A
CAS:931399-19-8
Inhibitor of prolyl 4-hydroxylase PHD
Formula:
C17H17FN2O5
Purity:
Min. 95%
Color and Shape:
Powder
Molecular weight:
348.33 g/mol
Ref: 3D-FG23706
| 1mg | 206.00 € | ||
| 5mg | 730.00 € | ||
| 10mg | 1,047.00 € |
Estimated delivery in United States, on Wednesday 18 Dec 2024
GSK360A
CAS:931399-19-8
GSK360A is a novel prolyl hydroxylase (PHD) domain-containing enzyme inhibitor.
Formula:
C17H17FN2O5
Purity:
98%
Color and Shape:
Solid
Molecular weight:
348.33
Ref: TM-T27476
| 25mg | 1,410.00 € | ||
| 50mg | 1,851.00 € | ||
| 100mg | 2,337.00 € |
Estimated delivery in United States, on Monday 27 Jan 2025
